Insmed (INSM) Stock Forecast & Price Target

Insmed is well positioned because Brinsupri is showing stronger-than-expected launch dynamics, with 2Q 2026 revenue of $309.2M and FY 2026 guidance raised to $1.25B-$1.4B, while better payer approval, compliance, and discontinuation trends support a larger U.S. treatable population and improved net pricing. Its Arikayce franchise remains a meaningful cash engine, with 2Q 2026 revenue of $116.3M, FY 2026 guidance of $450M-$470M, and U.S. pricing resets, an expanded frontline opportunity, and Japanese expansion providing additional runway despite a lower 2034 peak estimate of $1.5 billion. Beyond the commercial base, the company’s late-stage pipeline across TPIP, INS1148, brensocatib, and INS1201 adds further upside, while an international footprint led by the U.S. and Japan, plus positive phase 2 and phase 3 catalysts, supports a constructive long-term outlook.

Insmed is exposed to meaningful fundamental risk because its valuation depends heavily on the successful commercialization of Brinsupri, while any disappointment there could materially pressure investor sentiment and revenue expectations. The company also faces significant clinical and regulatory uncertainty across Arikayce and TPIP, including front-line NTM MAC lung disease and PH-ILD, PAH, and IPF, where both efficacy and approval outcomes remain uncertain. Competitive pressure further weakens the outlook, with TPIP facing established and emerging rivals such as Tyvaso and Yutrepia, even though Insmed reported about $1.2 billion of cash and cash equivalents at the end of 2Q 2026.